Devin Muntz
Biography
Devin Muntz is an associate in Baker McKenzie’s Chicago office and a member of the Firm’s Transactional Group. Devin’s practice focuses primarily on public and private company mergers and acquisitions, strategic investments, corporate partnering and licensing transactions, and other strategic corporate transactions. He advises clients in a variety of industries, with a particular focus on the technology and life sciences sectors.
Practice Focus
Devin’s practice focuses on all forms of mergers and acquisitions, including strategic acquirers and private equity sponsors on both the buy- and sell-side, as well as life sciences collaborations and licensing and other complex corporate transactions. Devin has experience representing technology clients, specifically in the fintech, software and crypto industries. In his work with clients in pharma, biotech, medical device and diagnostics, Devin brings knowledge in laboratory and clinical trial implementation and management, regulatory oversight and hospital wide quality improvement initiatives garnered from his experience working in two major health systems.
Representative Legal Matters
- Advised Abbott Laboratories in its acquisition of Cardiovascular Systems, Inc. for USD 890 million
- Advised AbbVie in numerous acquisitions and strategic transactions
- Advised Adobe in its acquisition of Brio XR and its acquisition of Rephrase.ai
- Advised Affirm in numerous acquisitions, acqui-hires and strategic transactions, including its acquisition of Returnly Technologies, Inc. for approximately USD 300 million
- Advised Armature Studio in its acquisition by Meta
- Advised Astellas in numerous strategic collaborations, including with Cullgen and Sutro Biopharma
- Advised Coinbase on numerous acquisitions and strategic transactions
- Advised Marel hf. in its pending EUR 3.5 billion sale to John Bean Technologies Corporation
- Advised Minoryx Therapeutics in its licensing transaction with Neuraxpharm for European rights to leriglitazone
- Advised Mountz, Inc., a leading developer and manufacturer of high-precision torque tools, in its approximately USD 40 million sale to Snap-on
- Advised Mysten Labs, a web3 infrastructure company, in its acquisition of certain assets from SuiNS Technologies Inc., an open, distributed naming service dedicated to the Sui blockchain
- Advised Safran SA in its pending USD 1.8 billion acquisition of Raytheon’s flight control and actuation business
- Advised Takeda in its sale of the global rights to the prescription brand Buccolam® to Neuraxpharm
- Advised Takeda in its strategic collaboration with KSQ Therapeutics to identify optimal T cell and NK cell gene targets screened using KSQ’s CRISPRomics technology and to develop and commercialize novel cell and non-cell immuno-oncology therapies
- Advised Takeda in its collaboration and license agreement with Poseida Therapeutics
- Advised Takeda in its co-development and co-commercialization license and collaboration with Protagonist Therapeutics for rusfertide
- Advised Uniphore in its acquisition of Jacada Ltd.
- Advised Yageo in its acquisition of Schneider Electric’s Telemecanique Sensors business at a valuation of EUR 723 million
Professional Associations and Memberships
- Chicago Bar Association – Member
- American Bar Association – Member
Admissions
- Illinois~United States (2018)
Education
- University of Chicago Law School (JD, with Honors) (2018)
- Princeton University (AB Molecular Biology) (2010)
Baker & McKenzie LLP is a Limited Liability Partnership organized under the laws of the State of Illinois (USA) and is a member of Baker & McKenzie International, a Verein organized under the laws of Switzerland.